List view / Grid view
WHO recommends IL-6 antagonists plus corticosteroids for hospitalised COVID-19 patients based on their ability to reduce risk of death and the need for mechanical ventilation.
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
15 May 2013 | By Sanofi
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials...
12 July 2011 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials...
